Sign up USA
Proactive Investors - Run By Investors For Investors

Tilray receives approval from US to import a medical cannabis study drug, shares soar almost 30%

The Canadian company’s medical cannabis product is being tested at the University of California San Diego as a treatment for a nerve disorder
Medical cannabis in pill form
Essential Tremor has extremely high prevalence rates with 0.4% of the general population suffering from it, and that figure rises to 6.3% among those 65 and older

Shares in Tilray Inc (NASDAQ:TLRY) shot up Tuesday after it announced that the US Drug Enforcement Administration (DEA) had approved the import of a Canadian cannabinoid study drug made by the company for a clinical trial at the University of California San Diego.  

Shares of the Canadian cannabis company shot up 28.95% to close at US$154.98 on Tuesday, having hit a 52-week high of US$155.10.

The stock then extended the rally by rising 5.81% to trade at US$163.99 in after-hours trade on Tuesday.

The university’s Center for Medicinal Cannabis Research (CMCR) is examining the pharmaceutical-grade medical cannabis product’s safety, tolerability and efficacy for essential tremor, a nervous system or neurological disorder that causes involuntary and rhythmic shaking.

Tilray is providing a cannabinoid formulation for the trial in capsule form, which will allow researchers to test an investigational drug product containing two active ingredients extracted from the cannabis plant, cannabidiol (CBD) and tetrahydrocannabinol (THC).

READ: Beverage giant Coca-Cola interested in cannabis drinks, sending cannabis stocks higher

Dr Fatta Nahab, a board-certified neurologist and director of the Functional Imaging of Neurodegenerative Disorders Lab at the UC San Diego Health’s Movement Disorder Center, will serve as the principal investigator for the study. The trial is expected to begin in early 2019 with financial support from Tilray and the International Essential Tremor Foundation.

“Tilray is proud to support this crucial research,” said Dr Catherine Jacobson, director of Clinical Research, at Tilray. “If this study can identify cannabinoids as a potential treatment for patients suffering from essential tremor, we can conduct further research and potentially provide alternative effective methods of relief for the high numbers of patients with essential tremor.”

Essential Tremor has extremely high prevalence rates; 0.4% of the general population suffers from it, and that figure rises to 4.6% to 6.3% among those 65 and older. Many patients do not experience relief with the current drugs on the market or find the side-effects of these drugs to be unbearable.

“It’s exciting to advance our work in this area by conducting a first-of-its kind trial of purified medicinal cannabis for a common neurological disorder like essential tremor,” says Dr Nahab. “Until now patients have been on their own to figure out the efficacy, safety, and dosing of cannabinoids. This trial should help answer many of these critical questions.”

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Join our Crypto, Blockchain and Cannabis Telegram group here
View full TLRY profile View Profile

Tilray Inc Timeline

Related Articles

1539364967_Cannabis-plant.jpg
October 10 2018
Management behind ICC International Cannabis Corp has a clear buy, build and sell strategy
cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use